Baird Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $103
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has maintained an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $83 to $103.
April 17, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joel Beatty reaffirmed an Outperform rating on Intra-Cellular Therapies and raised the price target to $103.
The increase in price target by Baird reflects a positive outlook on Intra-Cellular Therapies, suggesting confidence in the company's future performance. This endorsement from a reputable analyst is likely to instill investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100